Global biopharmaceutical enterprise GSK has officially announced the progression of its investigational mRNA seasonal influenza vaccine candidate into Phase III clinical evaluation following positive outcomes from its Phase II trials. The novel vaccine candidate utilizes advanced mRNA technology engineered to simultaneously target two major surface viral proteins—hemagglutinin and neuraminidase—a dual-target mechanism designed to generate broader immune protection and lower disease severity across diverse age demographics. Phase II clinical data demonstrated superior neutralizing antibody titers against both influenza A and B strains compared to standard and high-dose inactivated flu vaccines, while maintaining a strong safety profile. The global Phase III efficacy trial will evaluate the vaccine across large patient cohorts in both northern and southern hemisphere sites ahead of upcoming seasonal respiratory surges. Public health epidemiologists and infectious disease specialists highlight that incorporating neuraminidase-based immunity represents a critical evolution in flu immunization strategies, potentially mitigating viral escape mutations, reducing hospitalization rates, and providing durable cross-strain protection. Dual-Target mRNA Architecture Outperforms Standard and High-Dose ShotsPharmaceutical leader GSK announced plans to advance its investigational seasonal mRNA influenza vaccine candidate into Phase III clinical testing. The decision follows promising Phase II trial data presented at the Options XIII Conference for the Control of Influenza in Washington, D.C. The phase 2 results demonstrated that GSK's lead multivalent candidate generated higher immune responses across all evaluated influenza A and B strains compared to currently licensed age-appropriate standard-dose and high-dose flu shots, while maintaining an acceptable safety and reactogenicity profile. Overview: GSK Phase II mRNA Flu Vaccine Trial MetricsTrial & Candidate ParameterTrial Data & Development SpecificationsLead Candidate SelectedFLUm3HA.b-3NA (Encodes optimized B-strain HA + NA)Study Identifier & DesignFlu-028 (Randomized, observer-blind, 971 adult participants)Tested Age GroupsAdults 18–64 and older adults 65+Target AntigensDual-Target: Hemagglutinin (HA) & Neuraminidase (NA)Comparative EfficacyOutperformed standard-dose and high-dose licensed inactivated comparatorsRegulatory StatusFDA Fast Track Designation granted in July 2026Phase III LaunchSeptember 2026Targeting Neuraminidase to Overcome Traditional Vaccine GapsUnlike traditional licensed flu shots that focus almost exclusively on hemagglutinin (HA), GSK's investigational mRNA candidate is designed to target both HA and neuraminidase (NA)—the two primary surface glycoproteins that allow influenza viruses to bind to, infect, and spread between host cells. Growing scientific consensus indicates that eliciting strong antibodies against NA can reduce disease severity, improve cross-strain protection, and limit viral shedding. The selected candidate, FLUm3HA.b-3NA, specifically incorporates an optimized B-strain HA antigen paired with NA components to address historical immunity gaps seen in standard seasonal vaccines. FDA Fast Track Status and Global Market ImplicationsReflecting the urgent global need to improve seasonal flu prevention, the U.S. Food and Drug Administration (FDA) granted Fast Track designation to GSK’s candidate in July 2026. With seasonal influenza causing up to 650,000 deaths globally every year, GSK’s upcoming Phase III study will mark the world's first pivotal Phase III efficacy trial for a dual HA/NA-targeted mRNA seasonal flu vaccine. If successful, the platform could modernize GSK's respiratory vaccine portfolio and offer broader multi-strain protection to vulnerable populations.